Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The promise of menin inhibition in AML

In this video, Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares some insights into the promise of menin inhibition for the treatment of acute myeloid leukemia (AML), highlighting menin inhibitors under clinical investigation including revumenib and ziftomenib. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.